TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06496841
Drug: Ultrasound-guided suprazygomatic sphenopalatine ganglion block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
Study: NCT06102512
Drug: LOXO-783
Normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06442566
Drug: Buprenorphine Patch
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
Study: NCT04305769
Drug: Alanyl-glutamine
Normalized name: ALANYL-GLUTAMINE
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Study: NCT06196658
Drug: anti-EX02 CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg
Study: NCT06044233
Drug: STI-1558
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI-1558 test preparation and reference preparation
Study: NCT04934696
Drug: BMS-986166
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04934696
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05101265
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose.
Study: NCT05101265
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose
Study: NCT04892472
Drug: Pembrolizumab (MK-3475) 200 mg
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
Study: NCT04672980
Drug: RTX-321
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX-321 monotherapy
Study: NCT04964505
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT04964505
Drug: Uproleselan
Normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04964505
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00063869
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06328179
Drug: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VHEA -Induction Phase Regimen/Consolidation therapy after remission
Study: NCT05815316
Drug: 18F-PSMA-1007
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
Study: NCT06389344
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Study: NCT06248515
Drug: Sacituzumab govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
Study: NCT06271681
Drug: 23-valent pneumococcal polysaccharide vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
Study: NCT05293600
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
Study: NCT05293600
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
Study: NCT05293600
Drug: Atomoxetine and eszopiclone
Normalized name: Eszopiclone
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
Study: NCT05733741
Drug: Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.
Study: NCT05363501
Drug: IM Naloxone Injection
Normalized name: naloxone Injection
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
Study: NCT05363501
Drug: Naloxone Nasal Spray
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
Study: NCT05363501
Drug: Naloxone Nasal Swab
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg naloxone nasal swab administered in nostril
Study: NCT05363501
Drug: Naloxone Nasal Swab
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg naloxone nasal swab administered in nostril
Study: NCT05363501
Drug: Naloxone Nasal Swab
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 mg naloxone nasal swab administered in nostril
Study: NCT05363501
Drug: Naloxone Nasal Swab
Normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg naloxone nasal swab administered in nostril
Study: NCT05654701
Drug: Palopegteriparatide (TransCon PTH)
Normalized name: Palopegteriparatide
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
Study: NCT04229355
Drug: DEB-TACE plus Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
Study: NCT04229355
Drug: DEB-TACE plus Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
Study: NCT04229355
Drug: DEB-TACE plus PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
Study: NCT05446883
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT05446883
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion
Study: NCT05446883
Drug: Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT04741828
Drug: Vi-DT Typhoid Conjugate Vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Conjugate Vaccine
Study: NCT05085275
Drug: Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Normalized name: Ferric Citrate 1 GM Oral Tablet [AURYXIA]
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Study: NCT05720052
Drug: MS-553
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-553 oral tablet BID x 28-days
Study: NCT05152888
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
Study: NCT04779307
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV infusion.
Study: NCT04790279
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation of amlodipine 2.5 mg
Study: NCT04790279
Drug: NIFEdipine ER
Normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation of nifedipine ER 30 mg
Study: NCT04941183
Drug: NTR-441
Normalized name: 2-((HYDROXY((18-(4-(131I)IODOPHENYL)OCTADECYL)OXY)PHOSPHINYL)OXY)-N,N,NTRIMETHYLETHANAMINIUM INNER SALT
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTR-441
Study: NCT05439278
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
Study: NCT05825066
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study: NCT05825066
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study: NCT05225077
Drug: Dapagliflozin 10 MG [Farxiga]
Normalized name: dapagliflozin 10 MG [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
Study: NCT05798546
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
Study: NCT05798546
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
Study: NCT04770467
Drug: BRII-196 and BRII-198
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BRII-196 and BRII-198 given by intravenous administration
Study: NCT05562973
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive three psilocybin sessions, at least two weeks apart.
Study: NCT05686265
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
Study: NCT06148181
Drug: ABBV-141
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion; intravenous (IV)
Study: NCT06148181
Drug: ABBV-141
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection; subcutaneous (SC)
Study: NCT05753826
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg，D1，q3W
Study: NCT05773807
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
Study: NCT04806061
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium bicarbonate 8.4% to achieve urinary pH \>7.5
Study: NCT05222412
Drug: Iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Iptacopan
Study: NCT05914077
Drug: Secretin
Normalized name: Secretin
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
Study: NCT00000870
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000870
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000870
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000870
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000870
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000870
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04923737
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
Study: NCT04923737
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
Study: NCT06096090
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
Study: NCT05069597
Drug: CREON
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT05445921
Drug: Stellate Ganglion Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
Study: NCT04747236
Drug: Azacytidine
Normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacytidine, 300 mg po daily on Days 1-14
Study: NCT04747236
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
Study: NCT04747236
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
Study: NCT04747236
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
Study: NCT04747236
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
Study: NCT04927390
Drug: Mycophenolate Mofetil 500mg
Normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
Study: NCT05114707
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.